PMID: 7537874Apr 11, 1995Paper

An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers

Nucleic Acids Research
M A BonhamJ E Bisi

Abstract

The antisense activity and gene specificity of two classes of oligonucleotides (ONs) were directly compared in a highly controlled assay. One class of ONs has been proposed to act by targeting the degradation of specific RNAs through an RNase H-mediated mechanism and consists of C-5 propynyl pyrimidine phosphorothioate ONs (propyne-S-ON). The second class of antisense agents has been proposed to function by sterically blocking target RNA formation, transport or translation and includes sugar modified (2'-O-allyl) ONs and peptide nucleic acids (PNAs). Using a CV-1 cell based microinjection assay, we targeted antisense agents representing both classes to various cloned sequences localized within the SV40 large T antigen RNA. We determined the propyne-S-ON was the most potent and gene-specific agent of the two classes which likely reflected its ability to allow RNase H cleavage of its target. The PNA oligomer inhibited T Ag expression via an antisense mechanism, but was less effective than the propyne-S-ON; the lack of potency may have been due in part to the PNAs slow kinetics of RNA association. Interestingly, unlike the 2'-O-allyl ON, the antisense activity of the PNA was not restricted to the 5' untranslated region of the T Ag...Continue Reading

References

Nov 27, 1992·Science·J C HanveyK G Au
Dec 1, 1991·Pharmacology & Therapeutics·C A SteinL Yakubov
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·P DashP Goelet
May 31, 1994·Annals of the New York Academy of Sciences·J F MilliganM D Matteucci
Nov 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·N J PefferL E Babiss

❮ Previous
Next ❯

Citations

May 15, 2007·Amino Acids·P-C HuangK Sung
Apr 8, 2011·Journal of the American Society for Mass Spectrometry·Adrien NyakasStefan Schürch
Jul 13, 2001·Pharmacology & Therapeutics·C J Wraight, P J White
Jan 27, 2000·Journal of Biochemical and Biophysical Methods·K Jansen, E Richelson
May 12, 2000·Biochimica Et Biophysica Acta·H J LarsenP E Nielsen
Nov 10, 2000·Advanced Drug Delivery Reviews·D A Dean
May 30, 2001·Advanced Drug Delivery Reviews·R W TaylorR N Lightowlers
Nov 26, 2002·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Nathalie Dias, C A Stein
Feb 27, 1999·Current Opinion in Biotechnology·P E Nielsen
Jan 9, 1999·Bioorganic & Medicinal Chemistry·A H KrotzP E Nielsen
Jan 30, 2002·Drug Discovery Today·Vadim V Demidov
May 5, 2001·Biomolecular Engineering·M PoogaU Langel
Apr 29, 1998·Nature Biotechnology·L Good, P E Nielsen
Feb 1, 1997·Nature Structural Biology·H RasmussenP E Nielsen
Jun 21, 2002·Antisense & Nucleic Acid Drug Development·Uffe KoppelhusPeter Eigil Nielsen
Jan 1, 1996·Antisense & Nucleic Acid Drug Development·M PartridgeJ Summerton
Aug 1, 1997·Antisense & Nucleic Acid Drug Development·C ColombierM Leng
Aug 1, 1997·Antisense & Nucleic Acid Drug Development·R Häner, J Hall
Aug 1, 1997·Antisense & Nucleic Acid Drug Development·L Good, P E Nielsen
Jul 25, 2000·Antisense & Nucleic Acid Drug Development·R M HudziakP L Iversen
Jun 13, 2006·Oligonucleotides·S Bøe, E Hovig
Apr 6, 2006·Oligonucleotides·Kim A LennoxJohn M Dagle
Dec 25, 2007·Oligonucleotides·Zhaoyang YeRam I Mahato
Feb 1, 1996·Nucleic Acids Research·H Knudsen, P E Nielsen
Aug 31, 2002·Nucleic Acids Research·Valentina RapozziLuigi E Xodo
Jan 22, 2008·Nucleic Acids Research·Takumi IshizukaMakoto Komiyama
Dec 2, 2008·Nucleic Acids Research·Montserrat Terrazas, Eric T Kool
Apr 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·L Good, P E Nielsen
Aug 2, 2001·Proceedings of the National Academy of Sciences of the United States of America·A BeletskiiW M Strauss
Dec 27, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yun Mi BaeJoon Sig Choi
Mar 1, 2007·Expert Opinion on Drug Discovery·Joanna Opalinska
Feb 15, 2001·Expert Opinion on Investigational Drugs·P E Nielsen
Jul 23, 2004·Expert Opinion on Biological Therapy·Joseph A DiPaolo, Luis M Alvarez-Salas
Dec 1, 1996·Annals of Medicine·H Lönnberg, E Vuorio
Jan 12, 2016·Artificial DNA, PNA & XNA·Maria MocciaMichele Saviano
Apr 29, 2015·Advanced Drug Delivery Reviews·Eric Wickstrom

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.